{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-005679","form_type":"8-K","ticker":"APTOF","cik":"0000882361","company_name":"Aptose Biosciences Inc.","filed_at":"2023-09-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.862459+00:00","generated_at":"2026-06-10T21:33:07.272821+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aptose signs $7M investment agreement with Hanmi Pharmaceutical; first $3M tranche closed","bullets":["First tranche of $3.0M closed at $4.448/share (premium to $4.04 minimum price) for 668,449 shares.","Second tranche of $4.0M contingent on milestones: CofA, Lonza change orders, positive tuspetinib data by June 30, 2024.","Investor Rights Agreement: Hanmi gets nomination right (≥10% ownership) and participation right in future offerings.","Hanmi currently owns ~12.07% of APTO; second tranche capped at 19.99% blocker."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-005679","json":"https://secwatch.observer/filing/0001171843-23-005679.json","markdown":"https://secwatch.observer/filing/0001171843-23-005679.md","text":"https://secwatch.observer/filing/0001171843-23-005679.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882361/000117184323005679/0001171843-23-005679-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882361/000117184323005679/f8k_091123.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T21:33:07.272821+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0dd8210e41c3827b00c7f0ddce27336747e476eb","claim":"Aptose Biosciences Inc. entered into Subscription Agreement with Hanmi Pharmaceutical Co., Ltd. valued at up to $7,000,000 (effective 2023-09-06).","evidence_excerpt":"On September 6, 2023, Aptose Biosciences Inc., a Canadian corporation (the “ Corporation ”), entered into a subscription agreement (the “ Subscription Agreement ”) with Hanmi Pharmaceutical Co., Ltd., a corporation formed under the laws of the Republic of Korea (the “ Hanmi Pharmaceutical ”), pursuant to which the Corporation agreed to sell and issue to Hanmi Pharmaceutical and Hanmi Pharmaceutical agreed to purchase from the Corporation up to $7.0 million of the Corporation’s common shares","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882361/000117184323005679/0001171843-23-005679-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Hanmi Pharmaceutical Co., Ltd."},{"label":"Value","value":"up to $7,000,000"},{"label":"Effective","value":"2023-09-06"}],"fact_type":"material_agreement"},{"claim_id":"f5e025b78a2d76c2bf9b3876f0a3de028a4747a3","claim":"Aptose Biosciences Inc. entered into Investor Rights Agreement with Hanmi Pharmaceutical Co., Ltd. (effective 2023-09-06).","evidence_excerpt":"In connection with the Hanmi Investment, the Corporation and Hanmi Pharmaceutical entered into an Investor Rights Agreement (the “ Investor Rights Agreement ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882361/000117184323005679/0001171843-23-005679-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Hanmi Pharmaceutical Co., Ltd."},{"label":"Effective","value":"2023-09-06"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}